What does an incidence of 15 breast cancer cases per 1000 years of observation mean?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Understanding Breast Cancer Incidence: 15 Cases per 1000 Person-Years

The correct interpretation is that 15 out of 1000 women developed breast cancer during the observation period, which represents an incidence rate of 15 per 1000 person-years (or 1.5%), NOT 15%. 1

What This Number Actually Means

The incidence rate of 15 per 1000 person-years represents the number of new breast cancer cases detected during one year of observation in this population 1. This can also be expressed as:

  • 15 per 1000 women per year
  • 1500 per 100,000 women per year 1
  • 1.5% annual incidence (not 15%)

Clinical Context: Why This Rate Is Elevated

This detection rate of 15 per 1000 is substantially higher than typical population incidence rates and likely reflects a screening context rather than true population incidence 1:

  • Average population incidence in Europe: approximately 1.1 per 1000 (109.9 per 100,000) 2, 1
  • U.S. population incidence: approximately 1.24 per 1000 (124.2 per 100,000) 1

The elevated rate of 15 per 1000 suggests this represents a cancer detection rate (CDR) in a screening program, particularly in an enriched risk population 1. This is consistent with:

  • High-risk screening populations: CDRs of 8-29 per 1000 have been reported in BRCA mutation carriers and women with elevated risk 2, 1
  • Abbreviated MRI screening: demonstrates CDRs of 15 per 1000 in women with dense breasts and variable risk profiles 2, 1
  • Prevalent screening rounds: first-time screening detects both incident and pre-existing undiagnosed cancers, yielding higher detection rates than subsequent rounds 1

Important Caveats About This Detection Rate

Prevalent vs. Incident Screening

This 15 per 1000 rate likely represents a prevalent screen (first screening round) rather than steady-state incidence 1:

  • First screening round: detects accumulated prevalent cases (10-15 per 1000) 2, 1
  • Subsequent screening rounds: typically show lower CDRs of 3.7-5.3 per 1000 as prevalent cases are removed 1

Population Risk Factors

The American College of Radiology suggests this population likely has enriched risk factors 2, 1:

  • Dense breasts: relative risk 1.2 for heterogeneously dense, 2.1 for extremely dense 2
  • Family history: 19% of similar screening populations report first-degree relatives with breast cancer 2
  • Age distribution: breast cancer incidence increases steeply with age, with approximately 25% of cases occurring before age 50 1

Reservoir of Undetected Disease

To sustain a detection rate of several cancers per 1000 women annually, there must be a substantial reservoir of undetected breast cancers growing in the population 3. Mathematical modeling demonstrates that for every 3 breast tumors reaching 2 cm, there are approximately 57 additional tumors (39 smaller invasive carcinomas and 18 DCIS) that remain undetected "below the surface" 3.

Comparison to Standard Screening Outcomes

For context, standard mammography screening in average-risk populations yields much lower detection rates 2:

  • Digital breast tomosynthesis (DBT): 6 cancers per 1000 in women with dense breasts 2
  • Screening ultrasound: incremental CDR of 3.3 per 1000 overall, 5.1 per 1000 in dense breasts 2
  • Sestamibi MBI: incremental CDR of 7.7 per 1000 in women with dense breasts 2

The rate of 15 per 1000 is most consistent with high-sensitivity screening modalities (like MRI) in elevated-risk populations 2, 1.

References

Guideline

Breast Cancer Incidence Rate Interpretation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is the best interpretation of a cohort study finding that 30 out of 1000 people develop breast cancer per year in the general population?
With a family history of breast cancer in a first-degree relative, at what age should screening start?
What is the interpretation of an annual incidence of 15 breast cancer cases per 1000 people in a female population?
What is the interpretation of an incidence rate of 15 breast cancer diagnoses per 1000 individuals per year, detected by mammogram?
What are the current research trends in anesthesiology, excluding geriatrics?
What is a suitable replacement medication for a patient taking lisinopril (Angiotensin-Converting Enzyme (ACE) inhibitor) who requires an alternative due to side effects or other considerations?
What molecular tests, such as KRAS (Kirsten rat sarcoma viral oncogene homolog) and NRAS (Neuroblastoma RAS viral oncogene homolog), are needed for a patient with metastatic rectal cancer to guide treatment decisions?
How would you manage a 25-year-old female patient with bipolar spectrum disorder, history of self-harm, and current moderate depression, who is stable and denies current self-harm urges, regarding the continuation, tapering, or discontinuation of an off-label agent, and what would be the next pharmacologic step if her depression doesn't improve with optimized Bupropion (Wellbutrin) and Lamotrigine (Lamictal) therapy?
What are the best opioids to use or avoid in the emergency department for patients with impaired renal (kidney) function versus hepatic (liver) impairment, considering duration and onset of action?
What is the safe dose of metamizol (Dipyrone) syrup for pediatric patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.